- Home
- DOCS vs QGEN Comparison
DOCS vs QGEN Comparison
Compare DOCS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCS
- QGEN
- Stock Information
- Founded
- DOCS 2010
- QGEN 1986
- Country
- DOCS United States
- QGEN Netherlands
- Employees
- DOCS N/A
- QGEN N/A
- Industry
- DOCS Retail: Computer Software & Peripheral Equipment
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOCS Technology
- QGEN Health Care
- Exchange
- DOCS Nasdaq
- QGEN Nasdaq
- Market Cap
- DOCS 12.3B
- QGEN 10.7B
- IPO Year
- DOCS 2021
- QGEN 1996
- Fundamental
- Price
- DOCS $53.11
- QGEN $43.25
- Analyst Decision
- DOCS Buy
- QGEN Buy
- Analyst Count
- DOCS 20
- QGEN 7
- Target Price
- DOCS $69.55
- QGEN $50.68
- AVG Volume (30 Days)
- DOCS 1.5M
- QGEN 1.2M
- Earning Date
- DOCS 11-06-2025
- QGEN 11-04-2025
- Dividend Yield
- DOCS N/A
- QGEN 3.47%
- EPS Growth
- DOCS 42.88
- QGEN 331.20
- EPS
- DOCS 1.25
- QGEN 1.84
- Revenue
- DOCS $621,329,000.00
- QGEN $2,070,781,000.00
- Revenue This Year
- DOCS $13.54
- QGEN $7.37
- Revenue Next Year
- DOCS $11.26
- QGEN $5.65
- P/E Ratio
- DOCS $42.07
- QGEN $23.69
- Revenue Growth
- DOCS 20.21
- QGEN 5.32
- 52 Week Low
- DOCS $47.66
- QGEN $37.63
- 52 Week High
- DOCS $85.21
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- DOCS 20.76
- QGEN 29.58
- Support Level
- DOCS $65.22
- QGEN $42.82
- Resistance Level
- DOCS $67.10
- QGEN $47.39
- Average True Range (ATR)
- DOCS 2.13
- QGEN 1.06
- MACD
- DOCS -1.33
- QGEN -0.57
- Stochastic Oscillator
- DOCS 1.54
- QGEN 6.11
About DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).